Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Celgene
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT04245839 | https://clinicaltrials.gov/study/NCT01991457 | https://clinicaltrials.gov/study/NCT01585428 | https://clinicaltrials.gov/study/NCT02301143 | https://clinicaltrials.gov/study/NCT02033993 | https://clinicaltrials.gov/study/NCT07340398
Assets
Linked programs
- Fludarabine: Operational Burden Signal (2/5)
- nab-Paclitaxel: Operational Burden Signal (2/5)